Why the Admedus Ltd share price is 14% higher today

Biotech company Admedus Ltd (ASX:AHZ) shares surge higher following the release of its fourth quarter report. Is it time to get on board?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Whilst the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) may have started the day relatively flat, it certainly wasn't the case for Admedus Ltd (ASX: AHZ). The share price of the biotech company rocketed higher at the open and is currently up by over 14% at present.

The jump in its share price comes following the release of its fourth quarter report which showed a 40% increase in full year sales to $14.1 million. Furthermore, its full year forecast of sales growth of at least 50% in FY 2017 has no doubt gone down well with investors.

This growth is largely the result of its Infusion business being awarded a 5-year contract with the new Royal Adelaide Hospital for the installation of the arcomed Chroma Infusion pump system. It expects this contract to have a material impact on annual revenue starting in the first quarter of FY 2017.

Chairman and interim CEO Wayne Paterson anticipates its CardioCel product to also continue growing sales on a quarter on quarter basis. Although sales of the regenerative heart patch may have underwhelmed thus far, the company expects it to play a part in helping the company achieve profitability in FY 2018.

For the quarter the company reported a net cash loss of $4.4 million. This left it with a cash balance of $8.8 million and $3.5 million in research and development rebates expected in FY 2017. Thankfully for shareholders cost cutting is expected to reduce operating costs by $12 million during FY 2017, which should hopefully mean the company doesn't have to initiate any capital raising in the next 12 months.

Whilst I think there are positives to be found in an investment in Admedus, in the sector I personally have a preference for Pro Medicus Limited (ASX: PME) and REVA Medical Inc (ASX: RVA). Both companies are well worth researching further in my opinion.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »